Alembic Pharmaceuticals
APLLTD NSE
Alembic Pharmaceuticals
HealthcareNSE: APLLTD BSE: 533573 Pharmaceuticals
Key Fundamentals
SmallcapPharmaceuticalsHealthcareMarket Cap
₹15,755 Cr
Volatility
Moderate
P/E Ratio
22.99
EBITDA
₹1,173 Cr
Return on Equity
11.83%
Debt to Equity
0.25
Book Value
₹288.7
EPS
₹32.05
52W High
₹998
52W Low
₹635.8
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has been maintaining a healthy dividend payout of 35.7%
Weaknesses
5- Stock is trading at 2.81 times its book value
- The company has delivered a poor sales growth of 6.37% over past five years.
- Tax rate seems low
- Company has a low return on equity of 12.7% over last 3 years.
- Company might be capitalizing the interest cost
Growth Rate
Revenue Growth
10.2% higher than
3Y
Net Income Growth
15.26% lower than
3Y
Cash Flow Change
790% higher than
3Y
ROE
5.44% lower than
3Y
ROCE
-12.89% lower than
3Y
EBITDA Margin (Avg.)
1.28% lower than
3Y
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 2d agoAI opinion · based on fundamentals
Risk medium
Alembic Pharmaceuticals trades at a market cap of ₹15,755 Cr with a P/E of 23.3x and a dividend yield of 1.47%. TTM sales growth has accelerated to 14% and TTM profit growth stands at 26%, though the 5-year compounded profit CAGR remains negative at -9% and the stock has returned just 1% CAGR over 5 years, reflecting a mixed operating trajectory.
Bull Case 7
- TTM revenue growth has accelerated to 14%, well above the 5-year compounded sales CAGR of 6%, signaling improving top-line momentum
- TTM profit growth of 26% indicates a sharp earnings recovery and improving operating leverage
- 3-year compounded profit CAGR of 28% shows a sustained earnings rebound from the trough seen in prior years
- Consistent dividend payout ratio of 35.7% with a current yield of 1.47%, providing tangible shareholder returns
- 10-year compounded sales CAGR of 9% demonstrates a reasonable long-term revenue track record for a mid-cap pharma company
- 10-year ROE of 16% suggests the business has historically been capable of generating above-average returns on equity
- P/E of 23.3x is not excessive for a pharma company showing 26% TTM profit growth, implying the PEG ratio is below 1x on trailing numbers
Bear Case 8
- 5-year compounded profit CAGR is -9%, indicating that despite the recent recovery, earnings over a medium-term horizon have actually contracted
- 5-year compounded sales growth of only 6.37% is weak for a mid-cap pharma company operating in a high-growth domestic market
- Stock has delivered only 1% CAGR over 5 years and -14% over the last 1 year, significantly underperforming broader indices
- 3-year ROE of 12.7% is below the 15% threshold typically expected for quality compounders, and has declined from the 10-year average of 16%
- P/B of 2.83x is elevated relative to the current ROE of around 13%, suggesting the stock is not priced cheaply on an asset basis
- 10-year compounded profit CAGR of 0% means the company has generated no net earnings growth over a full decade
- Potential capitalization of interest costs may be flattering reported profitability, masking true operating expenses
- Apparently low tax rate raises questions about earnings quality and sustainability of reported net profit margins
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 2h ago Neutral 2
- Investor meetings scheduled Sep 1-2 Aug 27
Alembic Pharma scheduled one-to-one meetings with Dolat Capital, HSBC, and BOB Capital Markets on September 1-2, 2026. No unpublished price-sensitive information will be shared.
- New Company Secretary appointed Aug 20
Chirag Shukla appointed as Company Secretary and Compliance Officer effective August 20, 2026, bringing over 19 years of corporate secretarial and legal experience.
TL;DR: Recent news flow for Alembic Pharmaceuticals is limited and entirely routine, covering a standard investor meeting schedule and a compliance officer appointment. There are no material headwinds or positive catalysts in the current batch. The lack of negative news is reassuring, but investors should watch for updates from the Sep 1-2 analyst meetings for any forward-looking guidance.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,486 | 1,595 | 1,631 | 1,517 | 1,562 | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 | 1,876 | 1,848 | 2,150 |
| Expenses | 1,287 | 1,387 | 1,364 | 1,257 | 1,325 | 1,409 | 1,433 | 1,498 | 1,430 | 1,594 | 1,585 | 1,620 | 1,818 |
| Operating Profit | 199 | 208 | 266 | 260 | 237 | 239 | 260 | 271 | 281 | 316 | 292 | 228 | 332 |
| OPM % | 13% | 13% | 16% | 17% | 15% | 15% | 15% | 15% | 16% | 17% | 16% | 12% | 15% |
| Other Income | 12 | 10 | 3 | 4 | 2 | 30 | 10 | 14 | 6 | 8 | -27 | 2 | 15 |
| Interest | 14 | 16 | 15 | 11 | 13 | 19 | 22 | 25 | 24 | 24 | 23 | 23 | 28 |
| Depreciation | 66 | 68 | 69 | 69 | 69 | 71 | 70 | 69 | 74 | 76 | 80 | 89 | 98 |
| PBT | 130 | 135 | 185 | 183 | 157 | 180 | 178 | 192 | 190 | 224 | 162 | 119 | 222 |
| Tax % | 7% | -1% | 2% | 3% | 14% | 15% | 23% | 18% | 19% | 18% | 18% | -70% | 22% |
| Net Profit | 121 | 137 | 180 | 178 | 135 | 153 | 138 | 157 | 154 | 184 | 132 | 202 | 172 |
| EPS in Rs | 6.14 | 6.95 | 9.18 | 9.07 | 6.85 | 7.8 | 7.04 | 7.98 | 7.85 | 9.4 | 6.76 | 10.31 | 8.8 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,056 | 3,166 | 3,105 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 7,345 | 7,784 |
| Expenses | 1,653 | 2,159 | 2,490 | 2,488 | 3,061 | 3,383 | 3,913 | 4,432 | 4,970 | 5,296 | 5,664 | 6,224 | 6,617 |
| Operating Profit | 403 | 1,007 | 615 | 643 | 874 | 1,223 | 1,480 | 874 | 682 | 932 | 1,008 | 1,121 | 1,167 |
| OPM % | 20% | 32% | 20% | 21% | 22% | 27% | 27% | 16% | 12% | 15% | 15% | 15% | 15% |
| Other Income | 4 | 7 | 2 | 7 | 9 | -39 | 87 | 56 | -2 | 28 | 56 | -14 | -1 |
| Interest | 4 | 5 | 5 | 3 | 18 | 27 | 16 | 18 | 50 | 56 | 79 | 94 | 98 |
| Depreciation | 44 | 72 | 83 | 105 | 115 | 157 | 183 | 287 | 275 | 273 | 279 | 319 | 342 |
| PBT | 359 | 936 | 529 | 541 | 749 | 1,000 | 1,368 | 625 | 355 | 632 | 707 | 694 | 726 |
| Tax % | 21% | 23% | 23% | 22% | 21% | 20% | 19% | 17% | 4% | 3% | 18% | 3% | — |
| Net Profit | 283 | 720 | 403 | 413 | 583 | 801 | 1,146 | 521 | 342 | 616 | 582 | 671 | 690 |
| EPS in Rs | 15.01 | 38.2 | 21.39 | 21.89 | 31 | 43.97 | 58.33 | 26.5 | 17.4 | 31.33 | 29.68 | 34.33 | 35.27 |
| Div. Payout % | 23% | 9% | 19% | 18% | 18% | 23% | 24% | 38% | 46% | 35% | 37% | 35% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 38 | 38 | 38 | 38 | 38 | 38 | 39 | 39 | 39 | 39 | 39 | 39 |
| Reserves | 847 | 1,560 | 1,865 | 2,182 | 2,681 | 3,182 | 5,028 | 5,198 | 4,331 | 4,779 | 5,152 | 5,636 |
| Borrowings | 264 | 114 | 89 | 708 | 1,128 | 1,747 | 584 | 717 | 722 | 513 | 1,258 | 1,430 |
| Other Liabilities | 493 | 718 | 698 | 1,013 | 931 | 1,022 | 1,058 | 1,167 | 1,090 | 1,114 | 1,325 | 1,658 |
| Total Liabilities | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 | 8,763 |
| Fixed Assets | 547 | 708 | 799 | 993 | 1,158 | 1,552 | 1,788 | 1,798 | 2,398 | 2,547 | 2,524 | 3,081 |
| CWIP | 83 | 93 | 396 | 1,010 | 1,551 | 1,846 | 2,183 | 2,304 | 601 | 524 | 837 | 683 |
| Investments | 2 | 87 | 50 | 42 | 49 | 18 | 236 | 118 | 96 | 93 | 127 | 141 |
| Other Assets | 1,009 | 1,541 | 1,444 | 1,896 | 2,019 | 2,573 | 2,502 | 2,902 | 3,087 | 3,281 | 4,285 | 4,858 |
| Total Assets | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 | 8,763 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 172 | 948 | 329 | 312 | 812 | 449 | 1,463 | 552 | 724 | 803 | 88 | 783 |
| Investing | -256 | -307 | -486 | -884 | -756 | -731 | -840 | -372 | -448 | -321 | -568 | -506 |
| Financing | 87 | -224 | -129 | 503 | 59 | 155 | -597 | -217 | -262 | -438 | 444 | -164 |
| Net Cash Flow | 3 | 417 | -286 | -69 | 115 | -127 | 26 | -37 | 14 | 45 | -37 | 113 |
| Free Cash Flow | -52 | 647 | 348 | -495 | 49 | -285 | 804 | 128 | 282 | 487 | -466 | 290 |
| CFO/OP | 60 | 114 | 73 | 70 | 112 | 56 | 115 | 77 | 115 | 88 | 16 | 79 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 40 | 40 | 61 | 45 | 69 | 24 | 56 | 68 | 60 | 77 | 73 |
| Inventory Days | 196 | 266 | 269 | 302 | 356 | 417 | 431 | 406 | 315 | 350 | 466 | 462 |
| Days Payable | 166 | 264 | 213 | 313 | 237 | 220 | 194 | 178 | 145 | 157 | 179 | 154 |
| Cash Conversion Cycle | 94 | 42 | 96 | 51 | 164 | 266 | 261 | 283 | 237 | 253 | 363 | 381 |
| Working Capital Days | 32 | 36 | 61 | 69 | 24 | 50 | 73 | 74 | 77 | 88 | 87 | 87 |
| ROCE % | 38% | 66% | 29% | 22% | 23% | 24% | 26% | 11% | 7% | 13% | 13% | 13% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Alembic Pharmaceuticals insights
68 extracted metrics + investor summaries across FY11–FY27.
Documents
1
Intimation Regarding Successful Completion Of Unannounced USFDA Onsite Bioequivalence Inspection.
11 Sep - Alembic’s Vadodara bioequivalence facility passed unannounced USFDA inspection from 31 Aug-10 Sep 2026, with no Form 483 observations. 11 Sep - Alembic’s Vadodara bioequivalence facility passed unannounced USFDA inspection from 31 Aug-10 Sep 2026, with no Form 483 observations.
2
Compliances-Reg.24(A)-Annual Secretarial Compliance
2d - Annual Secretarial Compliance Report for FY ended 31 March 2026; no non-compliances observed. 2d - Annual Secretarial Compliance Report for FY ended 31 March 2026; no non-compliances observed.
4
Announcement under Regulation 30 (LODR)-Change in Management
4 May - Alembic Pharmaceuticals' AVP Sales & Marketing, Goldee Pardesi, resigned effective 4 May 2026. 4 May - Alembic Pharmaceuticals' AVP Sales & Marketing, Goldee Pardesi, resigned effective 4 May 2026.
5
Intimation Under Reg 30 Of SEBI (LODR), Regulations, 2015
4 May - Notice issued for transfer of unclaimed dividend shares to IEPF; claim deadline is 10/08/2026. 4 May - Notice issued for transfer of unclaimed dividend shares to IEPF; claim deadline is 10/08/2026.
Frequently Asked Questions about Alembic Pharmaceuticals
What does Alembic Pharmaceuticals Ltd do?
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.
Where is Alembic Pharmaceuticals Ltd (APLLTD) listed?
Alembic Pharmaceuticals Ltd trades as APLLTD on the NSE and under code 533573 on the BSE.
Which sector does Alembic Pharmaceuticals Ltd belong to?
Alembic Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd has a market capitalisation of ₹15,755 Cr, which places it in the Mid Cap band.
What is the PE ratio of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd trades at a PE ratio of 22.99, on earnings per share of ₹32.05, against a book value of ₹288.7 per share.
What is the 52-week high and low of Alembic Pharmaceuticals Ltd?
Over the last 52 weeks Alembic Pharmaceuticals Ltd has traded between ₹635.8 and ₹998.
Does Alembic Pharmaceuticals Ltd pay dividends?
Alembic Pharmaceuticals Ltd has a dividend yield of 1.47%.
What is the Return on Equity (ROE) of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd reported a return on equity of 11.83%. Its debt-to-equity ratio is 0.25.
Company Information
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.
Website alembic-india.com
CEO Mr. Chirayu Ramanbhai Amin
Employees 16,571
Listed 2011-09-20
Face Value ₹ 2
Issued Size 19,65,63,124
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/APLLTD.md for Alembic Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.